DAPI (dihydrochloride)

• Description:

  DAPI (4',6-Diamidino-2-phenylindole) dihydrochloride is a DAPI dye. DAPI is a fluorescent dye that binds strongly to DNA. It binds to the AT base pair of the double-stranded DNA minor groove, and one DAPI molecule can occupy three base pair positions. The fluorescence intensity of DAPI molecules bound to double-stranded DNA is increased by about 20 times, and it is commonly observed with fluorescence microscopy, and the amount of DNA can be determined based on the intensity of fluorescence. In addition, because DAPI can pass through intact cell membranes, it can be used to stain both live and fixed cells[1]. DAPI (Compound 3) is an acid-sensing ion channel 3 (ASIC3) inhibitor. DAPI binds to ASIC3 and blocks the channel function. DAPI can be used in the study of chronic pain treatment[2] (Ex/Em = 356/451 nm) .

• Product Name Alternative:

  4',6-Diamidino-2-phenylindole dihydrochloride

• UNSPSC:

  12171500

• Hazard Statement:

  H315, H317, H335

• Target:

  DNA Stain; Sodium Channel

• Type:

  Dye Reagents

• Related Pathways:

  Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/DAPI_dihydrochloride.html

• Purity:

  99.90

• Solubility:

  DMSO : 75 mg/mL (ultrasonic) |H2O : 5.56 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  N=C(C1=CC2=C(C=C1)C=C(C3=CC=C(C(N)=N)C=C3)N2)N.[H]Cl.[H]Cl

• Molecular Formula:

  C16H17Cl2N5

• Molecular Weight:

  350.25

• Precautions:

  H315, H317, H335

• References & Citations:

  [1]Kapuscinski J, et al. DAPI: a DNA-specific fluorescent probe. Biotech Histochem. 1995 Sep;70 (5) :220-33.|[2]Kuduk SD, et al. Amidine derived inhibitors of acid-sensing ion channel-3 (ASIC3) . Bioorg Med Chem Lett. 2009 Aug 1;19 (15) :4059-63. Sep;70 (5) :220-33.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, sealed storage, away from moisture and light)

• Scientific Category:

  Dye Reagents

• Clinical Information:

  No Development Reported

• Citation 01:

  ACS Appl Bio Mater. 2021 Jan 6.|ACS Appl Mater Interfaces. 2025 Mar 5;17 (9) :13461-13470.|ACS Nano. 2023 Jul 25;17 (14) :14079-14098.|Acta Biochim Biophys Sin (Shanghai) . 2021 Nov 10;53 (11) :1558-1566.|Acta Biomater. 2019 Sep 15:96:468-479.|Acta Pharm. 2025 Apr 10;75 (1) :103-118.|Acta Pharmacol Sin. 2021 Jul;42 (7) :1111-1123.|Adv Funct Mater. 2022: 2204636.|Adv Healthc Mater. 2025 Jan 22:e2404642.|Adv Sci (Weinh) . 2024 Dec 12:e2410495.|Adv Sci (Weinh) . 2024 Jun 21:e2400952.|Animals and Zoonoses. 2025 Sep 1.|Autophagy. 2022 Aug;18 (8) :1969-1981.|Biochem Pharmacol. 2023 Sep:215:115699.|Biochem Pharmacol. 2025 Jul 5:241:117130.|Biochem Pharmacol. 2025 Jun 19:117053.|Biochim Biophys Acta Mol Basis Dis. 2025 Apr 26;1871 (6) :167874.|Biochim Biophys Acta Mol Cell Res. 2025 Apr 29:119978.|Biol Direct. 2024 Dec 24;19 (1) :135.|Biomed Pharmacother. 2023 Oct:166:115399.|Biomed Pharmacother. 2024 Nov:180:117606.|Biomolecules. 2025 Feb 1;15 (2) :202.|bioRxiv. 2024 Dec 23:2024.12.22.627112.|bioRxiv. 2024 Dec 23:2024.12.22.629999.|bioRxiv. 2025 Jan 8:2024.11.28.625971.|bioRxiv. 2025 January 13.|bioRxiv. 2025 Jun 15.|bioRxiv. 2025 Oct 22.|Br J Cancer. 2025 Sep;133 (5) :697-708.|Cancer Lett. 2021 Apr 28;504:125-136.|Cancer Nanotechnol. 2024 Feb 22.|Cell Death Differ. 2024 May 23.|Cell Death Dis. 2025 May 5;16 (1) :361.|Cell Death Discov. 2024 Nov 1;10 (1) :462.|Cell Prolif. 2025 Jan;58 (1) :e13732.|Cell Rep. 2023 Jul 8;42 (7) :112789.|Cell Rep. 2024 Aug 30;43 (9) :114652.|Cell Res. 2022 Dec;32 (12) :1047-1067.|Cell Res. 2025 Dec;35 (12) :934-953.|Cell Tissue Res. 2023 Jun;392 (3) :811-826.|Chem Biol Interact. 2023 Sep 25:383:110681.|Chem Biol Interact. 2023 Sep 25:383:110684.|Clin Exp Pharmacol Physiol. 2025 Nov;52 (11) :e70072.|Compos B Eng. 2024 Jul 15.|Ecotoxicol Environ Saf. 2023 Jun 1:257:114940.|Eur J Med Chem. 2024 Dec 5:279:116866.|Eur J Med Chem. 2024 May 17:273:116507|Front Cell Dev Biol. 2021 Apr 15;9:665869.|Front Oncol. 2022 Mar 25;12:773654.|Glia. 2022 Feb;70 (2) :337-353.|Int Immunopharmacol. 2024 Jun 18:137:112431.|Int Immunopharmacol. 2025 Apr 6:154:114591.|Int J Biol Macromol. 2024 Jul 4:133652.|Int J Mol Sci. 2025 Apr 24;26 (9) :4033.|J Adv Res. 2025 Aug:74:609-620.|J Agric Food Chem. 2025 Sep 3;73 (35) :21976-21986.|J Biomed Sci. 2024 May 13;31 (1) :50.|J Cell Biochem. 2025 Apr;126 (4) :e70031.|J Clin Invest. 2024 Oct 22;134 (24) :e182217.|J Control Release. 2025 Apr 10:380:829-845.|J Ethnopharmacol. 2023 Jan 30:301:115855.|J Immunother Cancer. 2025 Feb 6;13 (2) :e010150.|J Mol Histol. 2025 Aug 8;56 (4) :259.|J Neuropathol Exp Neurol. 2020 Jul 1;79 (7) :734-745.|J Nucl Med. 2022 Jul;63 (7) :1039-1045. |J Oral Biosci. 2024 Sep 6:S1349-0079 (24) 00198-1.|Kaohsiung J Med Sci. 2022 Apr;38 (4) :357-366.|Light Sci Appl. 2022 Nov 11;11 (1) :324.|Microb Pathog. 2024 Feb:187:106527.|Mol Med Rep. 2021 Dec;24 (6) :832.|Mol Nutr Food Res. 2022 Apr;66 (7) :e2101088.|Nano Today. 2025 Oct.|Nat Commun. 2023 Aug 22;14 (1) :5111.|Nat Commun. 2024 Aug 10;15 (1) :6845.|Nat Commun. 2024 Sep 1;15 (1) :7603.|Nat Methods. 2024 Apr;21 (4) :680-691.|Oncotargets Ther. 2020 Oct 6;13:9941-9952.|Pathog Dis. 2024 May 31:ftae011.|Pharmaceuticals (Basel) . 2022 Jun 6;15 (6) :721.|Phytomedicine. 2020 Mar;68:153146.|Polymer. 2025 Sep 4;338:129019.|Redox Biol. 2025 Sep 10:87:103867.|Res Sq. 2024 Jul 29.|Res Sq. 2025 Jul 21.|Research (Wash D C) . 2024 Sep 12:7:0472.|Research (Wash D C) . 2025 Jul 17:8:0777.|Research Square Preprint. 2023 Oct 24.|Research Square Preprint. 2024 Dec 04.|Research Square Print. 2023 Feb 2.|Sci Rep. 2025 Aug 19;15 (1) :30411.|Sci Rep. 2025 Jul 11;15 (1) :25045.|Small. 2025 Oct 25:e09351.|SSRN. 2023 May 10.|SSRN. 2023 Sep 6.|SSRN. 2024 Jun 21.|STAR Protoc. 2025 Oct 11;6 (4) :104141.|Adv Funct Mater. 2025 Nov 3.|Biochem Pharmacol. 2026 Jan;243 (Pt 2) :117537.|Biomaterials. 2025 Sep 17:326:123723.|Cancer Res. 2025 Sep 18.|Free Radic Biol Med. 2025 Oct 25.|Int J Biol Macromol. 2026 Jan;335 (Pt 1) :149233.|Int J Mol Sci. 2025 Oct 16;26 (20) :10073.|Int J Pharm X. 2025 Nov 17:10:100448.|J Biochem Mol Toxicol. 2025 Oct;39 (10) :e70484.|J Control Release. 2025 Sep 30;388 (Pt 1) :114283.|Mol Cancer. 2025 Oct 2;24 (1) :238.|Brain Res Bull. 2025 Oct 28:232:111608.|Cell Death Discov. 2024 Oct 5;10 (1) :429.|Chem Biol Interact. 2025 Sep 3:111721.|Discov Oncol. 2025 Jan 9;16 (1) :27.|Int J Mol Med. 2026 Jan;57 (1) :26.|J Nanobiotechnology. 2025 Apr 29;23 (1) :325.|Mol Cancer. 2025 May 26;24 (1) :151.|Theranostics. 2025 Jan 20;15 (6) :2360-2374.|Comput Biol Med. 2025 Jul 5;196 (Pt A) :110721.|EMBO Mol Med. 2025 Oct 15.|Int Immunopharmacol. 2025 May 7:157:114764.|J Med Virol. 2025 Nov;97 (11) :e70699.|J Transl Med. 2025 Nov 10;23 (1) :1248.

• CAS Number:

  28718-90-3